EXPO vs ACA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 10, 2026

EXPO

44.3
AI Score
VS
EXPO Wins

ACA

38.6
AI Score

Investment Advisor Scores

EXPO

44score
Recommendation
HOLD

ACA

39score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric EXPO ACA Winner
Revenue 337.92M 1.23B ACA
Net Income 58.96M 366.30M ACA
Net Margin 17.4% 29.8% ACA
Operating Income 69.40M 131.40M ACA
ROE 20.4% 12.3% EXPO
ROA 9.0% 6.9% EXPO
Total Assets 652.72M 5.30B ACA
Cash 66.63M 432.10M ACA
Current Ratio 1.98 3.12 ACA
Free Cash Flow 25.69M -41.60M EXPO

Relative Price Performance (Last 90 Days)

EXPO 1M: -0.6% · 3M: +18.7% ACA 1M: 0.0% · 3M: +14.2%

Current Technical Phase

EXPO

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 45

RSI (14): 45.0 · Price: $67.21

ACA

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 52

RSI (14): 51.7 · Price: $145.00

Fundamentals Snapshot

Metric EXPO ACA
Market Cap
Forward P/E 23.7 28.3
Trailing P/E 30.2 32.5
Revenue (TTM)
Revenue Growth 0.1% 0.0%
Gross Margin 0.4% 0.2%
Operating Margin 0.2% 0.1%
EPS 2.23 4.47
Dividend Yield 0.02% 0.00%

Frequently Asked Questions

Based on our detailed analysis, EXPO is currently the stronger investment candidate, winning 3 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.